Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients

被引:96
作者
Fisher, Cynthia E. [1 ,2 ]
Knudsen, Janine L. [1 ]
Lease, Erika D. [1 ,3 ]
Jerome, Keith R. [2 ,4 ]
Rakita, Robert M. [1 ]
Boeckh, Michael [1 ,2 ]
Limaye, Ajit P. [1 ]
机构
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA
[3] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA
[4] Univ Washington, Dept Lab Med, Virol Div, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
cytomegalovirus; solid organ transplant; ganciclovir resistance; risk factors; outcomes; RAPID DETECTION; DISEASE; EMERGENCE; PROPHYLAXIS; FOSCARNET; SAMPLES; IMPACT; UL97; ERA;
D O I
10.1093/cid/cix259
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Ganciclovir-resistant (ganR) cytomegalovirus (CMV) is an emerging and important problem in solid organ transplant (SOT) recipients. Only through direct comparison of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk factors and outcomes attributable specifically to ganciclovir resistance appropriately be determined. Methods. We performed a retrospective, case-control (1: 3) study of SOT recipients with genotypically confirmed ganR-CMV (n = 37) and ganS-CMV infection (n = 109), matched by donor/recipient CMV serostatus, year and organ transplanted, and clinical manifestation. We used chi(2) (categorical) and Mann-Whitney (continuous) tests to determine predisposing factors and morbidity attributable to resistance, and Kaplan-Meier plots to analyze survival differences. Results. The rate of ganR-CMV was 1% (37/3467) overall and 4.1% (32/777) among CMV donor-positive, recipient-negative patients, and was stable over the study period. GanR-CMV was associated with increased prior exposure to ganciclovir (median, 153 vs 91 days, P<.001). Eighteen percent (3/17) of lung transplant recipients with ganR-CMV had received <6 weeks of prior ganciclovir (current guideline-recommended resistance testing threshold), and all non-lung recipients had received = 90 days (median, 160 [range, 90-284 days]) prior to diagnosis of ganR-CMV. GanR-CMV was associated with higher mortality (11% vs 1%, P = .004), fewer days alive and nonhospitalized (73 vs 81, P = .039), and decreased renal function (42% vs 19%, P = .008) by 3 months after diagnosis. Conclusions. GanR-CMV is associated with longer prior antiviral duration and higher attributable morbidity and mortality than ganS-CMV. Upcoming revised CMV guidelines should incorporate organ transplant-specific thresholds of prior drug exposure to guide rational ganR-CMV testing in SOT recipients. Improved strategies for prevention and treatment of ganR-CMV are warranted.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 50 条
  • [1] Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study
    Young, P. G.
    Rubin, J.
    Angarone, M.
    Flaherty, J.
    Penugonda, S.
    Stosor, V.
    Ison, M. G.
    TRANSPLANT INFECTIOUS DISEASE, 2016, 18 (03) : 390 - 395
  • [2] Incidence and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infections in 1244 Kidney Transplant Recipients
    Myhre, Hans-Arne
    Dorenberg, Dagny Haug
    Kristiansen, Knut Ivan
    Rollag, Halvor
    Leivestad, Torbjorn
    Asberg, Anders
    Hartmann, Anders
    TRANSPLANTATION, 2011, 92 (02) : 217 - 223
  • [3] Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature
    Rolling, Katherine E.
    Jorgenson, Margaret R.
    Descourouez, Jillian L.
    Mandelbrot, Didier A.
    Redfield, Robert R.
    Smith, Jeannina A.
    PHARMACOTHERAPY, 2017, 37 (10): : 1258 - 1271
  • [4] Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors
    Sabe, N.
    Gonzalez-Costello, J.
    Rama, I.
    Niubo, J.
    Bodro, M.
    Roca, J.
    Cruzado, J. M.
    Manito, N.
    Carratala, J.
    TRANSPLANT INTERNATIONAL, 2012, 25 (07) : e78 - e82
  • [5] Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection
    Avery, Robin K.
    Arav-Boger, Ravit
    Marr, Kieren A.
    Kraus, Edward
    Shoham, Shmuel
    Lees, Laura
    Trollinger, Brandon
    Shah, Pali
    Ambinder, Rich
    Neofytos, Dionysios
    Ostrander, Darin
    Forman, Michael
    Valsamakis, Alexandra
    TRANSPLANTATION, 2016, 100 (10) : E74 - E80
  • [6] Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
    Khurana, Mark P.
    Lodding, Isabelle P.
    Mocroft, Amanda
    Sorensen, Soren S.
    Perch, Michael
    Rasmussen, Allan
    Gustafsson, Finn
    Lundgren, Jens D.
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (06):
  • [7] The Use of Letermovir for Ganciclovir-Resistant Cytomegalovirus in Kidney Transplant Recipients
    Basic-Jukic, Nikolina
    Atic, Armin
    TURKISH JOURNAL OF NEPHROLOGY, 2022, 31 (03): : 257 - 260
  • [8] Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients
    Wong, Diana D.
    van Zuylen, Wendy J.
    Craig, Maria E.
    Rawlinson, William D.
    REVIEWS IN MEDICAL VIROLOGY, 2019, 29 (02)
  • [9] Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient
    Chen F.
    Bando T.
    Hanaoka N.
    Fukuse T.
    Hasegawa S.
    Wada H.
    The Japanese Journal of Thoracic and Cardiovascular Surgery, 2005, 53 (10) : 562 - 564
  • [10] Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature
    Hofmann, Eveline
    Sidler, Daniel
    Dahdal, Suzan
    Bittel, Pascal
    Suter-Riniker, Franziska
    Manuel, Oriol
    Walti, Laura N.
    Hirzel, Cedric
    TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (03)